Evidence map›Paper›PMID 41236560›Full record

ReviewPathologie (Heidelberg, Germany)2026

[Diffuse large B-cell lymphoma and Hodgkin lymphoma].

Sylvia Hartmann, Martin-Leo Hansmann

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Pathologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sylvia HartmannInstitut für Pathologie, Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Deutschland. sylvia.hartmann@uk-essen.de.
Martin-Leo HansmannInstitut für Pathologie, Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B‑cell lymphomas are highlighted within the group of high-grade B-cell lymphomas, as they represent one of the most common lymphoma types in our region. In addition, there are numerous rare entities that can often be suspected morphologically and clinically but need to be confirmed molecularly or through extended immunophenotyping panels. Hodgkin lymphomas are also common, characterized by a few typical tumor cells and a pronounced variability in their microenvironment, leading to classification into characteristic subtypes.

Indexed as

Hodgkin DiseaseLymphoma, Large B-Cell, DiffuseDiagnosis, DifferentialHumansImmunophenotypingTumor MicroenvironmentDifferential diagnosisDiffuse large B-cell lymphomaHistologyImmunohistochemistryImmunophenotyping

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.